BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-07 07:00 |
BOTHE_PR_2022-09-07_2022-H1_EN_vfinal.pdf
|
English | PDF • 298.4 KB | ||
| 2022-09-07 07:00 |
BOTHE_PR_2022-09-07_2022-H1_FR_vfinal.pdf
|
French | PDF • 364.2 KB | ||
| 2022-09-07 07:00 |
20220630_Bone Therapeutics_Interim Financial Report H1 2022_EN_final.pdf
|
English | PDF • 671.3 KB | ||
| 2022-09-07 07:00 |
20220630_Bone Therapeutics_Interim Financial Report H1 2022_FR_final.pdf
|
French | PDF • 667.9 KB | ||
| 2022-08-31 07:00 |
BOTHE_PR_2022-08-31_Denominator_EN_vfinal.pdf
|
English | PDF • 218.7 KB | ||
| 2022-08-31 07:00 |
BOTHE_PR_2022-08-31_Denominator_FR_vfinal.pdf
|
French | PDF • 230.1 KB | ||
| 2022-08-26 07:00 |
BOTHE_PR_2022-09-05_EGM1_EN_vfinal.pdf
|
English | PDF • 206.1 KB | ||
| 2022-08-26 07:00 |
BOTHE_PR_2022-09-05_EGM1_FR_vfinal.pdf
|
French | PDF • 219.3 KB | ||
| 2022-08-26 07:00 |
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_EN_Final.pdf
|
English | PDF • 192.2 KB | ||
| 2022-08-26 07:00 |
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_FR_Final.pdf
|
French | PDF • 193.6 KB | ||
| 2022-08-10 00:00 |
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_EN_Final.pdf
|
English | PDF • 192.2 KB | ||
| 2022-08-10 00:00 |
BOTHE_PR_2022-08-10_Contribution agreement Medsenic_FR_Final.pdf
|
French | PDF • 193.6 KB | ||
| 2022-07-29 07:30 |
BOTHE_PR_2022-07-29_Denominator_EN_vFinal.pdf
|
English | PDF • 221.0 KB | ||
| 2022-07-29 07:30 |
BOTHE_PR_2022-07-29_Denominator_FR_vFinal.pdf
|
French | PDF • 231.7 KB | ||
| 2022-07-15 01:00 |
BOTHE_PR_2022-07-15_ALLOB-TF2_Amendment_EN_vFinal.pdf
|
English | PDF • 222.8 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
